Discover
DYN
Dyne Therapeutics, Inc.
15.29
2 x 10.96
1 x 15.32
bid
ask
+
0.25
1.66%
2 @ 04:01 PM
15.29 +0.00 (0.00%)
| Ytd | -21.83% | |
| 1y | -7.50% |
15.04
day range
15.47
14.00
52 week range
27.30
| Open | 15.15 | Prev Close | 15.04 | Low | 15.04 | High | 15.47 | Mkt Cap | 2.86B |
| Vol | 2.07M | Avg Vol | 2.93M | EPS | -3.30 | P/E | N/A | Forward P/E | -4.58 |
| Beta | 1.12 | Short Ratio | 7.25 | Inst. Own | 103.65% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-05 | 50-d Avg | 20.98 | 200-d Avg | 19.45 | 1yr Est | 35.73 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-04 | 2026-09 | -0.91 | N/A | N/A | N/A |
| 2026-07-30 | 2026-06 | -0.75 | -1.08 | -0.33 | -44.23% |
| 2026-05-11 | 2026-03 | -0.77 | -0.73 | 0.04 | 5.48% |
| 2026-03-02 | 2025-12 | -0.74 | -0.76 | -0.02 | -2.70% |
| 2025-11-05 | 2025-09 | -0.81 | -0.76 | 0.05 | 6.17% |
| 2025-07-28 | 2025-06 | -0.99 | -0.97 | 0.02 | 2.02% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-09-30 | Chardan Capital | Upgrade | Buy | Buy |
| 2026-09-30 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-09-29 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2026-09-09 | Morgan Stanley | Upgrade | Overweight | Overweight |
| 2026-09-09 | JP Morgan | Downgrade | Neutral | Underweight |
| 2026-09-09 | RBC Capital | Upgrade | Outperform | Outperform |
Profile
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-03-10 | BESKROVNAYA OXANA | Officer | 195.84K | Sale |
| 2026-09-07 | COX JOHN | Chief Executive Officer | 429.51K | Sale |
| 2026-09-07 | FRIEDL-NADERER JOHANNA | Officer | 152.90K | Sale |
| 2026-09-07 | KERR DOUGLAS | Officer | 162.56K | Sale |
| 2026-07-26 | KERSTEN DIRK | Director | 0.00 | Sale |
| 2026-04-23 | LUBNER DAVID CHARLES | Director | 0.00 | Stock Gift |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | T. Rowe Price Investment Management, Inc. | 30.91M | 472.65M | 16.55% |
| 2026-06-29 | Blackrock Inc. | 12.40M | 189.66M | 6.64% |
| 2026-06-29 | Jupiter Topco LLC | 12.00M | 183.45M | 6.42% |
| 2026-06-29 | FMR, LLC | 11.21M | 171.36M | 6.00% |
| 2026-06-29 | State Street Corporation | 7.46M | 114.04M | 3.99% |
| 2026-06-29 | Orbis Allan Gray Ltd | 7.01M | 107.13M | 3.75% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | T. Rowe Price Small-Cap Stock Fund, Inc. | 7.00M | 107.10M | 3.75% |
| 2026-06-29 | T. Rowe Price Small-Cap Value Fund, Inc. | 4.60M | 70.37M | 2.46% |
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 4.47M | 68.37M | 2.39% |
| 2026-09-29 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 4.35M | 66.51M | 2.33% |
| 2026-08-30 | iShares Trust-iShares Russell 2000 ETF | 3.85M | 58.92M | 2.06% |
| 2026-06-29 | T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 3.81M | 58.25M | 2.04% |